Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 79 entries
Sorted by: Best Match Show Resources per page
EDITORIAL COMMENT.

Urology

Glick L, Vincent SA, Squadron D, Han TM, Syed K, Danella JF, Ginzburg S, Guzzo TJ, Lanchoney T, Raman JD, Smaldone M, Uzzo RG, Tomaszweski JJ, Reese A, Singer EA, Jacobs B, Trabulsi EJ, Gomella LG, Mann MJ.
PMID: 34489002
Urology. 2021 Sep;155:18. doi: 10.1016/j.urology.2021.02.044.

No abstract available.

Cite
Glick L, Vincent SA, Squadron D, et al. EDITORIAL COMMENT. Urology. 2021;155:18doi: 10.1016/j.urology.2021.02.044.
Glick, L., Vincent, S. A., Squadron, D., Han, T. M., Syed, K., Danella, J. F., Ginzburg, S., Guzzo, T. J., Lanchoney, T., Raman, J. D., Smaldone, M., Uzzo, R. G., Tomaszweski, J. J., Reese, A., Singer, E. A., Jacobs, B., Trabulsi, E. J., Gomella, L. G., & Mann, M. J. (2021). EDITORIAL COMMENT. Urology, 15518. https://doi.org/10.1016/j.urology.2021.02.044
Glick, Lydia, et al. "EDITORIAL COMMENT." Urology vol. 155 (2021): 18. doi: https://doi.org/10.1016/j.urology.2021.02.044
Glick L, Vincent SA, Squadron D, Han TM, Syed K, Danella JF, Ginzburg S, Guzzo TJ, Lanchoney T, Raman JD, Smaldone M, Uzzo RG, Tomaszweski JJ, Reese A, Singer EA, Jacobs B, Trabulsi EJ, Gomella LG, Mann MJ. EDITORIAL COMMENT. Urology. 2021 Sep;155:18. doi: 10.1016/j.urology.2021.02.044. PMID: 34489002.
Copy Download .nbib Format: NLM
Pain Management in Breast Cancer Patients: A Multidisciplinary Approach.

Cureus

Alhazmi LSS, Bawadood MAA, Aljohani AMS, Alzahrani AAR, Moshref L, Trabulsi N, Moshref R.
PMID: 34336485
Cureus. 2021 Jun 28;13(6):e15994. doi: 10.7759/cureus.15994. eCollection 2021 Jun.

Pain is a significant problem and is one of the most invalidating symptoms in breast cancer (BC) patients that would negatively affect the functional status and the Quality of Life (QoL). Pain management in BC patients requires thorough patient...

Cite
Alhazmi LSS, Bawadood MAA, Aljohani AMS, et al. Pain Management in Breast Cancer Patients: A Multidisciplinary Approach. Cureus. 2021;13(6):e15994doi: 10.7759/cureus.15994.
Alhazmi, L. S. S., Bawadood, M. A. A., Aljohani, A. M. S., Alzahrani, A. A. R., Moshref, L., Trabulsi, N., & Moshref, R. (2021). Pain Management in Breast Cancer Patients: A Multidisciplinary Approach. Cureus, 13(6), e15994. https://doi.org/10.7759/cureus.15994
Alhazmi, Lenah Sulaiman S, et al. "Pain Management in Breast Cancer Patients: A Multidisciplinary Approach." Cureus vol. 13,6 (2021): e15994. doi: https://doi.org/10.7759/cureus.15994
Alhazmi LSS, Bawadood MAA, Aljohani AMS, Alzahrani AAR, Moshref L, Trabulsi N, Moshref R. Pain Management in Breast Cancer Patients: A Multidisciplinary Approach. Cureus. 2021 Jun 28;13(6):e15994. doi: 10.7759/cureus.15994. eCollection 2021 Jun. PMID: 34336485; PMCID: PMC8318122.
Copy Download .nbib Format: NLM
Mature splenic teratoma: A rare case report.

International journal of surgery case reports

Kavagutti MS, Marques EBC, da Silva FS, Trabulsi MFM, Marini BRG.
PMID: 33412409
Int J Surg Case Rep. 2021 Jan;78:397-400. doi: 10.1016/j.ijscr.2020.11.082. Epub 2020 Nov 19.

INTRODUCTION: Teratomas are germ cell neoplasms that can be malignant or benign. Their occurrence is more prevalent in gonads, but there are rare extragonal reports, and splenic teratomas are exceptionally uncommon.CASE REPORT: A 44-year-old woman with a report of...

Cite
Kavagutti MS, Marques EBC, da Silva FS, et al. Mature splenic teratoma: A rare case report. Int J Surg Case Rep. 2020;78:397-400doi: 10.1016/j.ijscr.2020.11.082.
Kavagutti, M. S., Marques, E. B. C., da Silva, F. S., Trabulsi, M. F. M., & Marini, B. R. G. (2021). Mature splenic teratoma: A rare case report. International journal of surgery case reports, 78397-400. https://doi.org/10.1016/j.ijscr.2020.11.082
Kavagutti, Mayume Silva, et al. "Mature splenic teratoma: A rare case report." International journal of surgery case reports vol. 78 (2021): 397-400. doi: https://doi.org/10.1016/j.ijscr.2020.11.082
Kavagutti MS, Marques EBC, da Silva FS, Trabulsi MFM, Marini BRG. Mature splenic teratoma: A rare case report. Int J Surg Case Rep. 2021 Jan;78:397-400. doi: 10.1016/j.ijscr.2020.11.082. Epub 2020 Nov 19. PMID: 33412409; PMCID: PMC7803625.
Copy Download .nbib Format: NLM
Apiaceous vegetables protect against acrolein-induced pulmonary injuries through modulating hepatic detoxification and inflammation in C57BL/6 male mice.

The Journal of nutritional biochemistry

Redding MC, Pan JH, Kim YJ, Batish M, Trabulsi J, Lee JH, Kim JK.
PMID: 35016997
J Nutr Biochem. 2022 Jan 08;108939. doi: 10.1016/j.jnutbio.2022.108939. Epub 2022 Jan 08.

Acrolein (Acr) is a reactive aldehyde in the environment. Acr causes oxidative stress and a cascade of catalytic events and has, thereby, been associated with increased risk of pulmonary diseases. Whether apiaceous vegetables (API) consumption can prevent Acr-induced pulmonary...

Cite
Redding MC, Pan JH, Kim YJ, et al. Apiaceous vegetables protect against acrolein-induced pulmonary injuries through modulating hepatic detoxification and inflammation in C57BL/6 male mice. J Nutr Biochem. 2022;108939doi: 10.1016/j.jnutbio.2022.108939.
Redding, M. C., Pan, J. H., Kim, Y. J., Batish, M., Trabulsi, J., Lee, J. H., & Kim, J. K. (2022). Apiaceous vegetables protect against acrolein-induced pulmonary injuries through modulating hepatic detoxification and inflammation in C57BL/6 male mice. The Journal of nutritional biochemistry, 108939. https://doi.org/10.1016/j.jnutbio.2022.108939
Redding, Mersady C, et al. "Apiaceous vegetables protect against acrolein-induced pulmonary injuries through modulating hepatic detoxification and inflammation in C57BL/6 male mice." The Journal of nutritional biochemistry vol. (2022): 108939. doi: https://doi.org/10.1016/j.jnutbio.2022.108939
Redding MC, Pan JH, Kim YJ, Batish M, Trabulsi J, Lee JH, Kim JK. Apiaceous vegetables protect against acrolein-induced pulmonary injuries through modulating hepatic detoxification and inflammation in C57BL/6 male mice. J Nutr Biochem. 2022 Jan 08;108939. doi: 10.1016/j.jnutbio.2022.108939. Epub 2022 Jan 08. PMID: 35016997.
Copy Download .nbib Format: NLM
Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer.

Cureus

Alhumaid M, Sait S, Fallatah E, AlSayegh N, Farsi A, Nassif M, Farsi NJ, Akeel N, Samkari A, Shabkah AA, Trabulsi N.
PMID: 34786251
Cureus. 2021 Oct 11;13(10):e18670. doi: 10.7759/cureus.18670. eCollection 2021 Oct.

Among patients with metastatic colorectal cancer, 25% have isolated peritoneal carcinomatosis. We performed a systematic review and meta-analysis to assess the disease-free survival (DFS) and overall survival (OS) of patients undergoing hyperthermic intraperitoneal chemotherapy with oxaliplatin. Eleven studies were...

Cite
Alhumaid M, Sait S, Fallatah E, et al. Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer. Cureus. 2021;13(10):e18670doi: 10.7759/cureus.18670.
Alhumaid, M., Sait, S., Fallatah, E., AlSayegh, N., Farsi, A., Nassif, M., Farsi, N. J., Akeel, N., Samkari, A., Shabkah, A. A., & Trabulsi, N. (2021). Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer. Cureus, 13(10), e18670. https://doi.org/10.7759/cureus.18670
Alhumaid, Moayad, et al. "Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer." Cureus vol. 13,10 (2021): e18670. doi: https://doi.org/10.7759/cureus.18670
Alhumaid M, Sait S, Fallatah E, AlSayegh N, Farsi A, Nassif M, Farsi NJ, Akeel N, Samkari A, Shabkah AA, Trabulsi N. Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer. Cureus. 2021 Oct 11;13(10):e18670. doi: 10.7759/cureus.18670. eCollection 2021 Oct. PMID: 34786251; PMCID: PMC8579872.
Copy Download .nbib Format: NLM
Weight Changes in Women Receiving Chemotherapy for Non-Metastatic Breast Cancer in Saudi Arabia.

Cureus

Al-Hajeili M, Trabulsi N, Makin MA, Shibriq N, Alshelali R, Alghoraibi L, Alhaidari R, Alhazzani L, Alzahrani AS.
PMID: 33527066
Cureus. 2021 Jan 28;13(1):e12961. doi: 10.7759/cureus.12961.

Background Women with breast cancer (BC) commonly experience weight gain during chemotherapy, although there is conflicting evidence regarding the contributing factors. This study aimed to evaluate body weight changes among women undergoing chemotherapy for non-metastatic BC during the first...

Cite
Al-Hajeili M, Trabulsi N, Makin MA, et al. Weight Changes in Women Receiving Chemotherapy for Non-Metastatic Breast Cancer in Saudi Arabia. Cureus. 2021;13(1):e12961doi: 10.7759/cureus.12961.
Al-Hajeili, M., Trabulsi, N., Makin, M. A., Shibriq, N., Alshelali, R., Alghoraibi, L., Alhaidari, R., Alhazzani, L., & Alzahrani, A. S. (2021). Weight Changes in Women Receiving Chemotherapy for Non-Metastatic Breast Cancer in Saudi Arabia. Cureus, 13(1), e12961. https://doi.org/10.7759/cureus.12961
Al-Hajeili, Marwan, et al. "Weight Changes in Women Receiving Chemotherapy for Non-Metastatic Breast Cancer in Saudi Arabia." Cureus vol. 13,1 (2021): e12961. doi: https://doi.org/10.7759/cureus.12961
Al-Hajeili M, Trabulsi N, Makin MA, Shibriq N, Alshelali R, Alghoraibi L, Alhaidari R, Alhazzani L, Alzahrani AS. Weight Changes in Women Receiving Chemotherapy for Non-Metastatic Breast Cancer in Saudi Arabia. Cureus. 2021 Jan 28;13(1):e12961. doi: 10.7759/cureus.12961. PMID: 33527066; PMCID: PMC7842248.
Copy Download .nbib Format: NLM
Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation.

JCO precision oncology

Giri VN, Obeid E, Gross L, Bealin L, Hyatt C, Hegarty SE, Montgomery S, Forman A, Bingler R, Kelly WK, Dicker AP, Winheld S, Trabulsi EJ, Chen DYT, Lallas CD, Allen BA, Daly MB, Gomella LG.
PMID: 34164591
JCO Precis Oncol. 2017 May 04;1. doi: 10.1200/PO.16.00039. eCollection 2017 May.

PURPOSE: Multigene panels are commercially available for the evaluation of prostate cancer (PCA) predisposition, which necessitates tailored genetic counseling (GC) for men. Here we describe emerging results of Genetic Evaluation of Men, prospective multigene testing study in PCA to...

Cite
Giri VN, Obeid E, Gross L, et al. Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO Precis Oncol. 2017;1doi: 10.1200/PO.16.00039.
Giri, V. N., Obeid, E., Gross, L., Bealin, L., Hyatt, C., Hegarty, S. E., Montgomery, S., Forman, A., Bingler, R., Kelly, W. K., Dicker, A. P., Winheld, S., Trabulsi, E. J., Chen, D. Y. T., Lallas, C. D., Allen, B. A., Daly, M. B., & Gomella, L. G. (2017). Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO precision oncology, 1. https://doi.org/10.1200/PO.16.00039
Giri, Veda N, et al. "Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation." JCO precision oncology vol. 1 (2017). doi: https://doi.org/10.1200/PO.16.00039
Giri VN, Obeid E, Gross L, Bealin L, Hyatt C, Hegarty SE, Montgomery S, Forman A, Bingler R, Kelly WK, Dicker AP, Winheld S, Trabulsi EJ, Chen DYT, Lallas CD, Allen BA, Daly MB, Gomella LG. Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO Precis Oncol. 2017 May 04;1. doi: 10.1200/PO.16.00039. eCollection 2017 May. PMID: 34164591; PMCID: PMC8210976.
Copy Download .nbib Format: NLM
Transrectal Subharmonic Ultrasound Imaging for Prostate Cancer Detection.

Urology

Gupta I, Freid B, Masarapu V, Machado P, Trabulsi E, Wallace K, Halpern E, Forsberg F.
PMID: 31899231
Urology. 2020 Apr;138:106-112. doi: 10.1016/j.urology.2019.12.025. Epub 2019 Dec 30.

OBJECTIVE: To assess the prostate cancer (CaP) detection rates of contrast-enhanced, transrectal subharmonic ultrasound imaging (SHI).MATERIALS AND METHODS: This IRB-approved study enrolled 55 subjects. The initial 5 subjects were studied for SHI optimization, while the remaining 50 were evaluated...

Cite
Gupta I, Freid B, Masarapu V, et al. Transrectal Subharmonic Ultrasound Imaging for Prostate Cancer Detection. Urology. 2019;138:106-112doi: 10.1016/j.urology.2019.12.025.
Gupta, I., Freid, B., Masarapu, V., Machado, P., Trabulsi, E., Wallace, K., Halpern, E., & Forsberg, F. (2020). Transrectal Subharmonic Ultrasound Imaging for Prostate Cancer Detection. Urology, 138106-112. https://doi.org/10.1016/j.urology.2019.12.025
Gupta, I, et al. "Transrectal Subharmonic Ultrasound Imaging for Prostate Cancer Detection." Urology vol. 138 (2020): 106-112. doi: https://doi.org/10.1016/j.urology.2019.12.025
Gupta I, Freid B, Masarapu V, Machado P, Trabulsi E, Wallace K, Halpern E, Forsberg F. Transrectal Subharmonic Ultrasound Imaging for Prostate Cancer Detection. Urology. 2020 Apr;138:106-112. doi: 10.1016/j.urology.2019.12.025. Epub 2019 Dec 30. PMID: 31899231; PMCID: PMC7141967.
Copy Download .nbib Format: NLM
Dose escalation with proton-beam boost for low-risk prostate cancer.

Nature clinical practice. Urology

Trabulsi EJ, Valicenti RK.
PMID: 16691237
Nat Clin Pract Urol. 2006 May;3(5):256-7. doi: 10.1038/ncpuro0477.

No abstract available.

Cite
Trabulsi EJ, Valicenti RK. Dose escalation with proton-beam boost for low-risk prostate cancer. Nat Clin Pract Urol. 2006;3(5):256-7doi: 10.1038/ncpuro0477.
Trabulsi, E. J., & Valicenti, R. K. (2006). Dose escalation with proton-beam boost for low-risk prostate cancer. Nature clinical practice. Urology, 3(5), 256-7. https://doi.org/10.1038/ncpuro0477
Trabulsi, Edouard J, and Valicenti, Richard K. "Dose escalation with proton-beam boost for low-risk prostate cancer." Nature clinical practice. Urology vol. 3,5 (2006): 256-7. doi: https://doi.org/10.1038/ncpuro0477
Trabulsi EJ, Valicenti RK. Dose escalation with proton-beam boost for low-risk prostate cancer. Nat Clin Pract Urol. 2006 May;3(5):256-7. doi: 10.1038/ncpuro0477. PMID: 16691237.
Copy Download .nbib Format: NLM
Contrast-Enhanced Ultrasound and Shear Wave Elastography: Novel Methods for the Evaluation of Urethral Stricture Disease.

The Journal of urology

Chung PH, Leong JY, Machado P, Wessner CE, Trabulsi EJ, Halpern EJ, Eisenbrey JR, Forsberg F.
PMID: 34428090
J Urol. 2022 Jan;207(1):152-160. doi: 10.1097/JU.0000000000002146. Epub 2021 Aug 24.

PURPOSE: Urologists will benefit from an imaging modality which can assess intra and extraluminal characteristics of urethral strictures. We conducted a prospective pilot study evaluating the utility of contrast-enhanced ultrasound and shear wave elastography for the evaluation of bulbar...

Cite
Chung PH, Leong JY, Machado P, et al. Contrast-Enhanced Ultrasound and Shear Wave Elastography: Novel Methods for the Evaluation of Urethral Stricture Disease. J Urol. 2021;207(1):152-160doi: 10.1097/JU.0000000000002146.
Chung, P. H., Leong, J. Y., Machado, P., Wessner, C. E., Trabulsi, E. J., Halpern, E. J., Eisenbrey, J. R., & Forsberg, F. (2022). Contrast-Enhanced Ultrasound and Shear Wave Elastography: Novel Methods for the Evaluation of Urethral Stricture Disease. The Journal of urology, 207(1), 152-160. https://doi.org/10.1097/JU.0000000000002146
Chung, Paul H, et al. "Contrast-Enhanced Ultrasound and Shear Wave Elastography: Novel Methods for the Evaluation of Urethral Stricture Disease." The Journal of urology vol. 207,1 (2022): 152-160. doi: https://doi.org/10.1097/JU.0000000000002146
Chung PH, Leong JY, Machado P, Wessner CE, Trabulsi EJ, Halpern EJ, Eisenbrey JR, Forsberg F. Contrast-Enhanced Ultrasound and Shear Wave Elastography: Novel Methods for the Evaluation of Urethral Stricture Disease. J Urol. 2022 Jan;207(1):152-160. doi: 10.1097/JU.0000000000002146. Epub 2021 Aug 24. PMID: 34428090.
Copy Download .nbib Format: NLM
Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures.

Journal of clinical trials

Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K.
PMID: 24533253
J Clin Trials. 2012 Jan 21;2(1). doi: 10.4172/jctr.1000105.

In spite of the large number of nutrient-derived agents demonstrating promise as potential chemopreventive agents, most have failed to prove effectiveness in clinical trials. Critical requirements for moving nutrient-derived agents to recommendation for clinical use include adopting a systematic,...

Cite
Kumar N, Crocker T, Smith T, et al. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012;2(1)doi: 10.4172/jctr.1000105.
Kumar, N., Crocker, T., Smith, T., Connors, S., Pow-Sang, J., Spiess, P. E., Egan, K., Quinn, G., Schell, M., Sebti, S., Kazi, A., Chuang, T., Salup, R., Helal, M., Zagaja, G., Trabulsi, E., McLarty, J., Fazili, T., Williams, C. R., Schreiber, F., & Anderson, K. (2012). Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. Journal of clinical trials, 2(1), . https://doi.org/10.4172/jctr.1000105
Kumar, Nagi, et al. "Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures." Journal of clinical trials vol. 2,1 (2012). doi: https://doi.org/10.4172/jctr.1000105
Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan 21;2(1). doi: 10.4172/jctr.1000105. PMID: 24533253; PMCID: PMC3924733.
Copy Download .nbib Format: NLM
Maghemite Intercalated Montmorillonite as New Nanofillers for Photopolymers.

Nanomaterials (Basel, Switzerland)

Tarablsi B, Delaite C, Brendle J, Croutxe-Barghorn C.
PMID: 28348316
Nanomaterials (Basel). 2012 Nov 19;2(4):413-427. doi: 10.3390/nano2040413.

In this work, maghemite intercalated montmorillonite (γFe₂O₃-MMT)/polymer nanocomposites loaded with 1 or 2 wt.% of nanofillers were obtained by photopolymerization of difunctional acrylate monomers. The γFe₂O₃-MMT nanofillers were prepared by a new method based on the

Cite
Tarablsi B, Delaite C, Brendle J, et al. Maghemite Intercalated Montmorillonite as New Nanofillers for Photopolymers. Nanomaterials (Basel). 2012;2(4):413-427doi: 10.3390/nano2040413.
Tarablsi, B., Delaite, C., Brendle, J., & Croutxe-Barghorn, C. (2012). Maghemite Intercalated Montmorillonite as New Nanofillers for Photopolymers. Nanomaterials (Basel, Switzerland), 2(4), 413-427. https://doi.org/10.3390/nano2040413
Tarablsi, Bassam, et al. "Maghemite Intercalated Montmorillonite as New Nanofillers for Photopolymers." Nanomaterials (Basel, Switzerland) vol. 2,4 (2012): 413-427. doi: https://doi.org/10.3390/nano2040413
Tarablsi B, Delaite C, Brendle J, Croutxe-Barghorn C. Maghemite Intercalated Montmorillonite as New Nanofillers for Photopolymers. Nanomaterials (Basel). 2012 Nov 19;2(4):413-427. doi: 10.3390/nano2040413. PMID: 28348316; PMCID: PMC5304601.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 79 entries